Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 28, 2013; 19(48): 9359-9365
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9359
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9359
Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease
Alicia Algaba, Iván Guerra, Gema de la Poza, Fernando Bermejo, Department of Gastroenterology, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
Ángel Castaño, Víctor M Castellano, Montserrat López, Department of Pathology, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
Author contributions: All authors made substantial contributions to the concept and design of the study, acquisition, analysis and interpretation of data, and all of them read and approved the final version of the manuscript.
Correspondence to: Alicia Algaba, MSc, Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Camino del Molino, 2, Fuenlabrada, 28942 Madrid, Spain. alicia_algaba@hotmail.com
Telephone: +34-69-9646717 Fax: +34-91-6006175
Received: August 4, 2013
Revised: September 20, 2013
Accepted: October 19, 2013
Published online: December 28, 2013
Processing time: 163 Days and 18.1 Hours
Revised: September 20, 2013
Accepted: October 19, 2013
Published online: December 28, 2013
Processing time: 163 Days and 18.1 Hours
Core Tip
Core tip: Several studies have reported increased rates of colorectal cancer in patients with inflammatory bowel diseases but limited data are available regarding incidence of extraintestinal malignancies in these patients. The present study demonstrates a higher risk of urinary bladder cancer, mucinous cystadenoma of the appendix and of neuroendocrine tumors, and a low colorectal cancer risk, in patients with inflammatory bowel disease in our environment. We raised the question of whether current cancer screening strategies need to be reviewed and adapted to the characteristics of each patient.